Results 271 to 280 of about 521,761 (340)

Cardio‐microcurrent device treatment for heart failure with reduced ejection fraction: Results from the C‐MIC II open‐label randomized controlled trial

open access: yesEuropean Journal of Heart Failure, EarlyView.
Efficacy and Safety of C‐MIC Device in Patients with Heart Failure with Reduced Ejection Fraction. 6MWD, 6‐min walk distance; CI, confidence interval; KCCQ‐OSS, Kansas City Cardiomyopathy Questionnaire overall summary score; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.
Jesus E. Rame   +24 more
wiley   +1 more source

Characteristics and outcomes of patients with heart failure and history of malignancy: Data from Swedish Heart Failure Registry and the National Cancer Register

open access: yesEuropean Journal of Heart Failure, EarlyView.
Prevalence and predictors of, and outcome associated with history of cancer in patients with heart failure. AF, atrial fibrillation; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CV, cardiovascular; DM, diabetes mellitus; EF, ejection fraction; GDMT, guideline‐directed medical therapy; GI, gastrointestinal; Hb, haemoglobin; HF ...
Pietro Ameri   +13 more
wiley   +1 more source

Atrial cardiomyopathy: From healthy atria to atrial failure. A clinical consensus statement of the Heart Failure Association of the ESC

open access: yesEuropean Journal of Heart Failure, EarlyView.
The diagnosis of atrial cardiomyopathy (AtCM) requires electrical atrial dysfunction, with evidence of either mechanical atrial dysfunction, atrial enlargement, or excessive atrial fibrosis. The diagnostic cut‐points presented are for standard electrocardiogram and echocardiogram studies (see Figure 1 for further detail).
Jerremy Weerts   +26 more
wiley   +1 more source

Shifts in <i>bla</i> genes and Class 1 integron prevalence in beta-lactamase-producing bacteria before and after the COVID-19 pandemic in Mendoza, Argentina. [PDF]

open access: yesMicrobiol Spectr
Márquez-Friedrichs F   +9 more
europepmc   +1 more source

Randomized investigation of heart failure therapy in patients with advanced cancer at risk of cardiac wasting: Rationale and design of the EMPATICC trial

open access: yesEuropean Journal of Heart Failure, EarlyView.
EMPower the heArt of patients with TermInal Cancer using Cardiac medicines (EMPATICC). eGFR, estomated glomerular filtration rate; EP, endpoint; FCM, ferric carboxymaltose; LVEF, left ventricular ejection fraction; N‐terminal pro‐B‐type natriuretic peptide; PGA, patient global assessment; PoC, proof of concept; QoL, quality of life; UICC, Union for ...
Markus S. Anker   +23 more
wiley   +1 more source

Home - About - Disclaimer - Privacy